Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02215


To evaluate the effects of VSL#3 on symptoms associated with diarrhea predominant IBS

Study summary:

The study will evaluate 2 doses of VSL#3 and placebo over a 4 week period in patients presenting with diarrhea predominant IBS symptoms.


Inclusion Criteria: - IBS diarrhea Exclusion Criteria: - < 18 years of age - Pregnancy/breast feeding - concomitant medications to reduce bowel function

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS

Official Title:

A Randomized, Multi-center, Double-blind, Placebo Controlled, Dose Ranging Study With VSL#3 in Diarrhea Predominant IBS Patients

Overall Status:


Study Phase:




Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Beth Israel Deaconess Medical Center

Oversight Authority:

United States: Institutional Review Board

Reasons Why Stopped:

Lack of enrollment

Study Type:


Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Anthony Lembo, MD
Principal Investigator
Beth Israel Deaconess Medical Center

Study Dates

Start Date:January 2005
Completion Date:January 2006
Completion Type:Actual
Primary Completion Date:January 2006
Primary Completion Type:Actual
Verification Date:February 2019
Last Changed Date:February 26, 2019
First Received Date:September 13, 2005

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Changes in bloating
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Changes in abdominal pain
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Frequency of bowel movements
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Global improvement in IBS symptoms
Safety Issues:False

Study Interventions

Intervention Type:Drug

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Beth Israel Deaconess Medical Center

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Results Reference
Citation:Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study. Clin Nutr. 2005 Dec;24(6):925-31. Epub 2005 Jul 27.

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.